Cover Image
市場調查報告書

競爭企業分析:Avastin、Cyramza、Eylea、Lucentis的抗VEGF/R生技仿製藥及 Bio-Superior

Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - 2017 Update

出版商 La Merie Publishing 商品編碼 358307
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
競爭企業分析:Avastin、Cyramza、Eylea、Lucentis的抗VEGF/R生技仿製藥及 Bio-Superior Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - 2017 Update
出版日期: 2017年11月02日 內容資訊: 英文 58 Pages
簡介

以血管內皮層生長因子 (VEGF) 或VEGF受體 (VEGF-R) 為標的治療抗體,2015年整體銷售額為150億美元,是極為成功的產品類別。Avastin是多年的生技藥品暢銷者,不過,視網膜疾病治療用的抗VEGF產品,Lucentis、Eylea,2015年第一次記錄了比癌症治療用的抗VEGF/R產品高的銷售額。

本報告提供各種癌症的症狀、視網膜疾病的治療所採用的血管內皮層生長因子 (VEGF) 此外關於以其受體 (VEGF-R) 為標的之重組抗體領域中的競爭產品評價,在各產品的銷售額、症狀的組合、開發平台,標的抗體、蛋白質的開發中現在進行中的計劃相關資訊等。

第1章 癌症中抗VEGF/R上市藥

  • Avastin、Zaltrap、Cyramza的銷售額
  • Avastin的銷售額及症狀的組合
  • Zaltrap的銷售額及症狀的組合
  • Cyramza的銷售額及症狀的組合

第2章 Avastin、Zaltrap的抗VEGF Bio-Superior

  • 癌症中抗VEGF Bio-Superior的開發平台
  • 癌症的雙特異性抗VEGF的開發平台

第3章 Cyramza的抗VEGF-R Bio-Superior

  • 癌症中抗VEGF-R Bio-Superior的開發平台
  • 癌症的雙特異性抗VEGF-R的開發平台

第4章 癌症的Avastin生技仿製藥的開發平台

第5章 眼科中抗VEGF上市藥

  • Lucentis、Eylea的銷售額
  • Lucentis的銷售額及症狀的組合
  • Eylea的銷售額及症狀的組合

第6章 Lucentis、Eylea的抗VEGF Bio-Superior

  • 眼科中抗VEGF Bio-Superior
  • 眼科的 Bio-Superior雙特異性抗VEGF、抗VEGF並用藥

第7章 眼科其他的抗VEGF分子

第8章 眼科的Lucentis的生技仿製藥

第9章 眼科的Eylea的生技仿製藥

第10章 眼科中抗VEGF的非標籤藥物使用 (非適應症使用)

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: LMCA0124

The Competitive Intelligence Report “Anti-VEGF & Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - a 2017 Update” provides a competitor evaluation in the field of recombinant antibodies, proteins and vaccines targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) for treatment of a variety of cancer indications and retinal diseases as of November 2017.

Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) are a highly successful class of products as evidenced by total sales of US$ 16 bln in 2016. Sales of anti-VEGF ophthalmic products continue to rise, while Avastin has come to an inflection point, also by the first approval of an Avastin biosimilar by the FDA.

The forthcoming patent expiries in the major markets have attracted a number of companies with global development of Avastin biosimilars in advanced clinical stages.

So far, less attention has been paid to anti-VEGF antibodies used for treatment of ophthalmic diseases although the approved antibody products are attractive targets for the second wave of biosimilar antibodies because of the impressive market growth fueled by the clinical success and patent expiries in the mid-term.

The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies, proteins or vaccines for treatment of cancer and neo-angiogenic eye diseases. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents

Oncology

1) Marketed Products in Oncology

  • Avastin, Zaltrap & Cyramza Sales 2008 - 2016
  • Avastin Sales & Indication Portfolio
  • Zaltrap Sales & Indication
  • Cyramza Sales & Indication Portfolio

2) Biosuperiors in Oncology

  • Anti-VEGF Biosuperiors of Avastin
  • Bispecific Anti-VEGF Biosuperiors of Avastin
  • Bispecific Anti-VEGF Proteins
  • Anti-VEGF-R Biosuperiors of Cyramza
  • Anti-VEGF-R Vaccines
  • Bispecific Anti-VEGF-R Biosuperiors of Cyramza

3) Biosimilars in Oncology

  • Avastin Biosimilars in Global Development
  • Avastin Biosimilar Developments in Less Regulated Markets
  • Avastin Biosimilar Developments in Early Stages

Ophthalmology

4) Marketed Products in Ophthalmology

  • Lucentis & Eylea Sales 2008 - 2016
  • Eylea Sales & Indication Portfolio
  • Lucentis Sales & Indication Portfolio
  • Lang Mu Sales & Indication Portfolio

5) Biosuperiors in Ophthalmology

  • Antibody-Mediated Anti-VEGF Biosuperiors in Ophthalmology
  • Other Anti-VEGF Biosuperiors in Ophthalmology

6) Biosimilars in Ophthalmology

  • Lucentis Biosimilars
  • Eylea Biosimilars
Back to Top